Pacific Edge is looking to open its first US franchise to market bladder cancer detection test, Cxbladder(R), by the end of the year.
The New Zealand business is joining Pennsylvania research facility Hershey Center for Applied Research (HCAR), and plans to set up shop next to its technology suites.
The project will open in August and provide state-subsidised lab and office suites for technology companies.
The Pacific Edge facility will serve as an office and processing facility for analysis of the Cxbladder(R) test, which uses the genes in a patient's urine to detect the presence of bladder cancer.
The launch of the franchise also calls for approximately 100 people to be hired in Pennsylvania over the next three years.
Pacific Edge chief executive David Darling said it was looking to build a better understanding of the US marketplace and the needs of local urologists, and selected HCAR because of its "direct engagement in nearly every aspect of the company's US commercialisation to date".
"HCAR executive director, Jack Atchason, and his staff helped us understand the marketplace and the needs of our top prospects," Darling said. "His 18-plus years of Biotech/Pharma commercialisation experience was a big asset in helping us build key elements of our plan."
The HCAR has strategic partnerships with Penn State University and the Penn State Milton S. Hershey Medical Center, and works closely with the state's department of economic development.